Porat Ruth purchased $12K of BX (indirect holdings)

Porat Ruth purchased 84 indirectly-held shares of Blackstone Inc. (BX) at $137.32 on 2026-08-10.

Original reporting
SEC EDGAR · Porat Ruth
Published Aug 12, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BX
Neutral
low confidence
Mentioned
$BX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BXNeutralLow
01

Why it matters

The newest fact is the director’s open-market purchase details (84 shares at $137.3156) and the post-transaction indirect holdings figure.

02

Market read

A modest director purchase is disclosed, but there is no fundamental catalyst tied to BX in the text.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but that alone does not establish conviction or timing advantage without additional context.

Relevance 3/10Novelty 2/10Timing: Filed on 2026-08-12 after the 2026-08-10 purchase.

Background

The article is a SEC Form 4 insider transaction disclosure for Blackstone Inc. (BX).

Company-level read

Ticker impact

$BXNeutralLow confidence
Context

Porat Ruth, a Blackstone director, filed a Form 4 for an open-market purchase of 84 shares at $137.3156 on 2026-08-10.

Expected impact

Low likelihood of a sustained price move; any reaction would be limited and short-lived.

Evidence & confidence

The disclosure is primary-source but the transaction size ($11,540.96) is modest, and there is no accompanying guidance, deal, or regulatory development.

Market effects

No clear sector read-through from a small director buy.

None indicated.

None indicated.

Counterpoint

Director buys can be routine and may not reflect a strong forward view, especially at small dollar amounts.

Key entities

  • Blackstone Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Porat Ruth

    Director who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BXMedAI 8/10

Blackstone Life Sciences announces $455M collaboration with Boston Scientific

Blackstone Life Sciences (BX) and Boston Scientific (BSX) are collaborating on a $455M project to develop the VITALYST heart pump system. This is the first co-funding deal between the two companies. The system aims to treat acute myocardial infarction cardiogenic shock by improving blood flow. BXLS sees potential in the technology to enhance current mechanical circulatory support devices.